Citizen Petition Spotlights Risks for Patients on Drug Proven to Have No Benefit in Improving Cardiovascular Outcomes and Need for Urgent Regulatory Action to Protect Patients Citizen Petition Spotlights Risks for Patients on Drug Proven to Have No Benefit in Improving Cardiovascular Outcomes and Need for Urgent Regulatory Action to
Amarin Corporation Plc (AMRN) just unveiled an announcement. At the Company’s Annual Meeting, shareholders congregated to cast their votes on several key resolutions, with an impressive 61% of the shares
Amarin Corporation announced shareholder approval of all proposed resolutions specified at its 2024 Annual General Meeting. Importantly, shareholders approved each of the two proposals required for the Company to proceed
– Shareholders Approve Share Repurchase Program of up to $50 Million – – Shareholders Approve Share Repurchase Program of up to $50 Million –
Amarin Corporation highlighted three data presentations at ACC.24 showcasing the mechanistic activity of Eicosapentaenoic acid, including the potential effects of EPA on endothelial cell dysfunction and on oxidation of samples